488 related articles for article (PubMed ID: 27428964)
1. Pneumococcus and the Elderly in Italy: A Summary of Available Evidence Regarding Carriage, Clinical Burden of Lower Respiratory Tract Infections and On-Field Effectiveness of PCV13 Vaccination.
Orsi A; Ansaldi F; Trucchi C; Rosselli R; Icardi G
Int J Mol Sci; 2016 Jul; 17(7):. PubMed ID: 27428964
[TBL] [Abstract][Full Text] [Related]
2. Streptococcus pneumoniae serotype 3 is masking PCV13-mediated herd immunity in Canadian adults hospitalized with community acquired pneumonia: A study from the Serious Outcomes Surveillance (SOS) Network of the Canadian immunization research Network (CIRN).
LeBlanc JJ; ElSherif M; Ye L; MacKinnon-Cameron D; Ambrose A; Hatchette TF; Lang ALS; Gillis HD; Martin I; Demczuk W; Andrew MK; Boivin G; Bowie W; Green K; Johnstone J; Loeb M; McCarthy AE; McGeer A; Semret M; Trottier S; Valiquette L; Webster D; McNeil SA
Vaccine; 2019 Aug; 37(36):5466-5473. PubMed ID: 31345638
[TBL] [Abstract][Full Text] [Related]
3. Effects of 13-valent pneumococcal conjugate vaccination of adults on lower respiratory tract infections and antibiotic use in primary care: secondary analysis of a double-blind randomized placebo-controlled study.
van Werkhoven CH; Bolkenbaas M; Huijts SM; Verheij TJM; Bonten MJM
Clin Microbiol Infect; 2021 Jul; 27(7):995-999. PubMed ID: 32971253
[TBL] [Abstract][Full Text] [Related]
4. Pneumococcal Conjugated Vaccine Reduces the High Mortality for Community-Acquired Pneumonia in the Elderly: an Italian Regional Experience.
Baldo V; Cocchio S; Gallo T; Furlan P; Romor P; Bertoncello C; Buja A; Baldovin T
PLoS One; 2016; 11(11):e0166637. PubMed ID: 27846277
[TBL] [Abstract][Full Text] [Related]
5. Post hoc analysis of the efficacy of the 13-valent pneumococcal conjugate vaccine against vaccine-type community-acquired pneumonia in at-risk older adults.
Suaya JA; Jiang Q; Scott DA; Gruber WC; Webber C; Schmoele-Thoma B; Hall-Murray CK; Jodar L; Isturiz RE
Vaccine; 2018 Mar; 36(11):1477-1483. PubMed ID: 29429807
[TBL] [Abstract][Full Text] [Related]
6. [Immunization campaign with 13-valent Pneumococcal Conjugate Vaccine in adults in Liguria Region, Italy: one year post-introduction preliminary results].
Orsi A; Ansaldi F; Durando P; Turello V; Icardi G;
Epidemiol Prev; 2014; 38(6 Suppl 2):66-72. PubMed ID: 25759347
[TBL] [Abstract][Full Text] [Related]
7. [Recommendations for prevention of community-acquired pneumonia with bacteremia as the leading form of invasive pneumococcal infections in the population of people over 50 years of age and risk groups above 19 years of age].
Albrecht P; Antczak A; Hryniewicz W; Skoczyńska A; Radzikowski A; Kedziora-Kornatowska K; Bernatowska E; Stompór T; Grodzicki T; Gyrczuk E; Imiela J; Jedrzejczak W; Windak A
Pol Merkur Lekarski; 2014 Feb; 36(212):79-87. PubMed ID: 24720101
[TBL] [Abstract][Full Text] [Related]
8. Serotype distribution and antimicrobial susceptibilities of nasopharyngeal isolates of Streptococcus pneumoniae from healthy children in the 13-valent pneumococcal conjugate vaccine era.
Zuccotti G; Mameli C; Daprai L; Garlaschi ML; Dilillo D; Bedogni G; Faccini M; Gramegna M; Torresani E; ; Ballerini E; Benincaso A; Bonvissuto M; Bricalli D; Brioschi M; Calloni CS; Camiletti MI; Colella G; De Angelis L; Decarlis S; Di Nello F; Dozzi M; Galli E; Gandini V; Giuliani MG; Laviola F; Loda B; Macedoni M; Mazzucchi E; Metta MG; Moscatiello A; Nannini P; Petruzzi M; Picicco D; Picciotti M; Pisanelli S; Porta N; Ramponi G; Redaelli F; Rubini R; Sala N; Saitta V; Scelza G; Tiso RM; Tomasetto M; Torcoletti M; Travaini M; Valentini M; Vessia C
Vaccine; 2014 Jan; 32(5):527-34. PubMed ID: 24342249
[TBL] [Abstract][Full Text] [Related]
9. The Impact of the 13-Valent Pneumococcal Conjugate Vaccine on Pneumococcal Carriage in the Community Acquired Pneumonia Immunization Trial in Adults (CAPiTA) Study.
van Deursen AMM; van Houten MA; Webber C; Patton M; Scott D; Patterson S; Jiang Q; Gruber WC; Schmoele-Thoma B; Grobbee DE; Bonten MJM; Sanders EAM
Clin Infect Dis; 2018 Jun; 67(1):42-49. PubMed ID: 29324986
[TBL] [Abstract][Full Text] [Related]
10. Pneumococcal serotypes in adults hospitalized with community-acquired pneumonia in Greece using urinary antigen detection tests: the EGNATIA study, November 2017 - April 2019.
Liapikou A; Konstantinidis A; Kossyvaki V; Skiadas J; Menegas D; Méndez C; Beavon R; Begier E; Gessner BD; Milionis H; Tsimihodimos V; Baxevanos G; Argiriadou T; Terrovitou C; Toumbis M;
Hum Vaccin Immunother; 2022 Nov; 18(5):2079923. PubMed ID: 35703733
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of 13-valent pneumococcal conjugate vaccine (PCV13) versus that of 7-valent PCV (PCV7) against nasopharyngeal colonization of antibiotic-nonsusceptible Streptococcus pneumoniae.
Dagan R; Juergens C; Trammel J; Patterson S; Greenberg D; Givon-Lavi N; Porat N; Gurtman A; Gruber WC; Scott DA
J Infect Dis; 2015 Apr; 211(7):1144-53. PubMed ID: 25355940
[TBL] [Abstract][Full Text] [Related]
12. Effectiveness of the 23-valent pneumococcal polysaccharide vaccine against community-acquired pneumonia in older individuals after the introduction of childhood 13-valent pneumococcal conjugate vaccine: A multicenter hospital-based case-control study in Japan.
Nakashima K; Suzuki K; Aoshima M; Murabata M; Kondo K; Ohfuji S; Fukushima W; Maeda A; Hirota Y;
Vaccine; 2022 Nov; 40(46):6589-6598. PubMed ID: 36184405
[TBL] [Abstract][Full Text] [Related]
13. Pneumococcal conjugate vaccine use in adults - Addressing an unmet medical need for non-bacteremic pneumococcal pneumonia.
Sings HL
Vaccine; 2017 Sep; 35(40):5406-5417. PubMed ID: 28602602
[TBL] [Abstract][Full Text] [Related]
14. Distribution of 13-valent pneumococcal conjugate vaccine Streptococcus pneumoniae serotypes in US adults aged ≥50 years with community-acquired pneumonia.
Sherwin RL; Gray S; Alexander R; McGovern PC; Graepel J; Pride MW; Purdy J; Paradiso P; File TM
J Infect Dis; 2013 Dec; 208(11):1813-20. PubMed ID: 24092845
[TBL] [Abstract][Full Text] [Related]
15. Burden of pneumococcal community-acquired pneumonia in adults across Europe: A literature review.
Torres A; Cillóniz C; Blasi F; Chalmers JD; Gaillat J; Dartois N; Schmitt HJ; Welte T
Respir Med; 2018 Apr; 137():6-13. PubMed ID: 29605214
[TBL] [Abstract][Full Text] [Related]
16. A post-hoc analysis of serotype-specific vaccine efficacy of 13-valent pneumococcal conjugate vaccine against clinical community acquired pneumonia from a randomized clinical trial in the Netherlands.
Gessner BD; Jiang Q; Van Werkhoven CH; Sings HL; Webber C; Scott D; Gruber WC; Grobbee DE; Bonten MJM; Jodar L
Vaccine; 2019 Jul; 37(30):4147-4154. PubMed ID: 31155413
[TBL] [Abstract][Full Text] [Related]
17. Experience with pneumococcal polysaccharide conjugate vaccine (conjugated to CRM197 carrier protein) in children and adults.
Durando P; Faust SN; Fletcher M; Krizova P; Torres A; Welte T
Clin Microbiol Infect; 2013 Oct; 19 Suppl 1():1-9. PubMed ID: 24083785
[TBL] [Abstract][Full Text] [Related]
18. Effectiveness of 13-Valent Pneumococcal Conjugate Vaccine Against Medically Attended Lower Respiratory Tract Infection and Pneumonia Among Older Adults.
Lewnard JA; Bruxvoort KJ; Fischer H; Hong VX; Grant LR; Jódar L; Cané A; Gessner BD; Tartof SY
Clin Infect Dis; 2022 Sep; 75(5):832-841. PubMed ID: 34967907
[TBL] [Abstract][Full Text] [Related]
19. 13-Valent Pneumococcal Conjugate Vaccine: A Review of Its Use in Adults.
Plosker GL
Drugs; 2015 Sep; 75(13):1535-46. PubMed ID: 26242768
[TBL] [Abstract][Full Text] [Related]
20. The Community-Acquired Pneumonia immunization Trial in Adults (CAPiTA): what is the future of pneumococcal conjugate vaccination in elderly?
van Werkhoven CH; Bonten MJ
Future Microbiol; 2015; 10(9):1405-13. PubMed ID: 26347153
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
